Matthew E Bourcier

Summary

Affiliation: Eastern Virginia Medical School
Country: USA

Publications

  1. ncbi Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma)
    Matthew E Bourcier
    Strelitz Diabetes Center and Neuroendocrine Unit, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA
    Pancreas 42:348-52. 2013
  2. ncbi Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases
    Matthew E Bourcier
    Strelitz Diabetes Center and Neuroendocrine Unit, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23510, USA
    J Clin Endocrinol Metab 94:3157-62. 2009

Detail Information

Publications2

  1. ncbi Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma)
    Matthew E Bourcier
    Strelitz Diabetes Center and Neuroendocrine Unit, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, USA
    Pancreas 42:348-52. 2013
    ..Studies have shown that the tyrosine kinase inhibitor sunitinib significantly prolongs progression-free survival in patients with pancreatic NETs. Here, we present 2 case reports of sunitinib in patients with different types of NETs...
  2. ncbi Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases
    Matthew E Bourcier
    Strelitz Diabetes Center and Neuroendocrine Unit, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, Virginia 23510, USA
    J Clin Endocrinol Metab 94:3157-62. 2009
    ..A continuous infusion of octreotide lowered the blood glucose levels further. He required diazoxide, a thiazide diuretic, phenytoin, and a constant infusion of glucose to control the hypoglycemia and elevated insulin levels...